Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Aravind Kalluri

Cardiovascular Disease Chicago, IL Medical Doctor

NPI 1184179335 CMS profile 11453215

240 E Huron St Ste 1-200, Chicago, IL 60611

Open in the dashboard

General payments

$29,117

119 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aravind Kalluri of Chicago, IL is reported in the CMS Open Payments database as having received $29,117 across 119 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $26,426 80
2024 General $2,654 38
2023 General $37 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aravind Kalluri
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Aravind Kalluri were reported at $26,426. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Aravind Kalluri Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $0 $335 $101–$1,037 $132
2022 $0 $395 $121–$1,211 $149
2023 $37 $443 $136–$1,283 $160
2024 $2,654 $450 $136–$1,323 $164
2025 $26,426 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Biosense Webster, Inc. $9,190 3 payments
  2. Abbott Laboratories $7,197 30 payments
  3. Boston Scientific Corporation $6,276 52 payments
  4. Medtronic, Inc. $5,856 20 payments
  5. Amgen Inc. $149 1 payment
  6. Biotronik Inc. $104 1 payment
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $89 3 payments
  8. Abiomed $76 2 payments
  9. Inari Medical, Inc. $48 1 payment
  10. Cardiva Medical, Inc. $25 1 payment
  11. Other $109 5 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Consulting Fee $9,000 1 payment
  2. Grant $8,545 3 payments
  3. Food and Beverage $6,136 88 payments
  4. Travel and Lodging $4,861 24 payments
  5. Education $574 3 payments
Products named General payments · program years 2023–2025
  1. General - Therapies General - Therapies_EP $3,546 9 payments
  2. TACTICATH $2,727 1 payment
  3. ASSURITY $1,818 1 payment
  4. GALLANT $1,609 15 payments
  5. FARAPULSE $1,497 12 payments
  6. ENSITE Structural Heart $752 11 payments
  7. Stingray $303 3 payments
  8. General - Therapies General - Therapies_CRM $278 2 payments
  9. ENSITE Electrophysiology $272 1 payment
  10. AVVIGO Guidance System $217 18 payments
  11. Other $1,078 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

119 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record